preeclampsia
Conditions
Interventions
Experimental group:Disclosure of SIRT1's serum level
control group:SIRT1's serum level is blinded
Cohort for PE prediction:None
Cohort for SIRT1’s reference value:None
Sponsors
Obstetrics and Gynecology Hospital of Fudan University
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Part I: Determination of serum SIRT1 reference range Inclusion criteria: early gestation at our hospital and willingness to deliver at our hospital, no underlying disease, age = 18 years, singleton, signed informed consent at the time of card creation, consent to use the individual's biological specimen for medical research. Part II: Evaluation of the predictive value of serum SIRT1 in early pregnancy for the development of preeclampsia Inclusion criteria: carded at our hospital in early pregnancy and willing to deliver at our hospital, age =18 years, singleton, signed informed consent at carding, and consent to use the individual's biological specimen for medical research. Part III: Whole-group randomized controlled trial with a stepwise design to assess serum SIRT1 levels in patients with suspected pre-eclampsia Inclusion criteria: Pregnant women =18 years of age, 20+0 to 36+6 weeks of gestation, singleton, with suspected preeclampsia (e.g., new or increased hypertension only, or at least one of the following: proteinuria, epigastric pain, headache with visual disturbance, fetal growth retardation, abnormal maternal blood tests), who were admitted to our institution.
Exclusion criteria
Exclusion criteria: Part I: Determination of serum SIRT1 reference range Exclusion criteria: missed visits, transfer for personal factors, termination of pregnancy before 20 weeks of gestation, occurrence of hypertensive disorders of pregnancy. Part II: Assessment of the predictive value of serum SIRT1 in early pregnancy for the development of pre-eclampsia Exclusion criteria: missed visits, transfer for personal factors, termination of pregnancy before 20 weeks of gestation. Part III: Whole-group randomized controlled trial with a stepwise design to assess serum SIRT1 levels in patients with suspected preeclampsia Exclusion criteria: missed visits, personal factor transfer, diagnosis of preeclampsia, HELLP syndrome, or eclampsia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SIRT1;preeclampsia yes or not;the interval from suspective preeclampsia to confirmed preeclampsia; | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence of the composite adverse maternal and fetal/neonatal outcomes;the use of spasmolytic agents and antihypertension therapy; | — |
Countries
China
Contacts
Public ContactWeirong Gu
Obstetrics and Gynecology Hospital of Fudan University
Outcome results
None listed